{"title":"治疗3年以上女性骨质疏松症的演变","authors":"J.A. Olmo Fernández-Delgado , M. Canteras Jordana","doi":"10.1016/S1132-8460(09)73228-3","DOIUrl":null,"url":null,"abstract":"<div><p>We are going to show the progress of 41 postmenopausal patients who have followed treatment for more than three years (86 months). Assessing several factors such as: development of the bone mineral density (BMD), adherence to therapeutic treatment, incidence of fractures and risk factors. Thirty five patients (85%) showed increases of the BMD in the spine with an average increase of 21%, and presented statistic changes (p<!--> <!--><<!--> <!-->0.005); 63% presented statistic changes in the hip but with not significant increases. Thirteen patients showed some fracture through fragility and 6 of them suffered more than one episode. By order of frequency: vertebral (spinal) fractures 8 (19.5%), radius 5 (12%), epiphysis of humerus 3 (7, 5%) and hip 2 (5%).</p><p>The most used treatment was alendronate (71%), followed by raloxifene (58%) and risedronate (54%). Using the Morisky test, the 48% of the patients were reliable.</p><p>We have found correlation between increases of the BMD and risk of fracture, not being found related to other risk factors.</p></div>","PeriodicalId":101109,"journal":{"name":"Revista Espa?ola de Enfermedades Metabólicas óseas","volume":"18 3","pages":"Pages 45-50"},"PeriodicalIF":0.0000,"publicationDate":"2009-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1132-8460(09)73228-3","citationCount":"1","resultStr":"{\"title\":\"Evolución de mujeres con osteoporosis tratadas durante más de tres años\",\"authors\":\"J.A. Olmo Fernández-Delgado , M. Canteras Jordana\",\"doi\":\"10.1016/S1132-8460(09)73228-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>We are going to show the progress of 41 postmenopausal patients who have followed treatment for more than three years (86 months). Assessing several factors such as: development of the bone mineral density (BMD), adherence to therapeutic treatment, incidence of fractures and risk factors. Thirty five patients (85%) showed increases of the BMD in the spine with an average increase of 21%, and presented statistic changes (p<!--> <!--><<!--> <!-->0.005); 63% presented statistic changes in the hip but with not significant increases. Thirteen patients showed some fracture through fragility and 6 of them suffered more than one episode. By order of frequency: vertebral (spinal) fractures 8 (19.5%), radius 5 (12%), epiphysis of humerus 3 (7, 5%) and hip 2 (5%).</p><p>The most used treatment was alendronate (71%), followed by raloxifene (58%) and risedronate (54%). Using the Morisky test, the 48% of the patients were reliable.</p><p>We have found correlation between increases of the BMD and risk of fracture, not being found related to other risk factors.</p></div>\",\"PeriodicalId\":101109,\"journal\":{\"name\":\"Revista Espa?ola de Enfermedades Metabólicas óseas\",\"volume\":\"18 3\",\"pages\":\"Pages 45-50\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2009-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/S1132-8460(09)73228-3\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista Espa?ola de Enfermedades Metabólicas óseas\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1132846009732283\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Espa?ola de Enfermedades Metabólicas óseas","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1132846009732283","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Evolución de mujeres con osteoporosis tratadas durante más de tres años
We are going to show the progress of 41 postmenopausal patients who have followed treatment for more than three years (86 months). Assessing several factors such as: development of the bone mineral density (BMD), adherence to therapeutic treatment, incidence of fractures and risk factors. Thirty five patients (85%) showed increases of the BMD in the spine with an average increase of 21%, and presented statistic changes (p < 0.005); 63% presented statistic changes in the hip but with not significant increases. Thirteen patients showed some fracture through fragility and 6 of them suffered more than one episode. By order of frequency: vertebral (spinal) fractures 8 (19.5%), radius 5 (12%), epiphysis of humerus 3 (7, 5%) and hip 2 (5%).
The most used treatment was alendronate (71%), followed by raloxifene (58%) and risedronate (54%). Using the Morisky test, the 48% of the patients were reliable.
We have found correlation between increases of the BMD and risk of fracture, not being found related to other risk factors.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
